Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label Sym004 in metastatic colorectal cancer with acquired anti-EGFR resistance and ECD-EGFR mutation
2016-000621-39Phase 2Completed
- Sponsor
- Symphogen
- Start
- Sep 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of futuximab + modotuximab in colorectal cancer (CRC) and metastatic colorectal adenocarcinoma (mCRC), sponsored by Symphogen. Primary endpoint: Overall response rate. Started Sep 2016; status: completed.
02
Drugs
futuximab + modotuximab
03
Conditions
colorectal cancer (CRC)metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2016-000621-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000621-39.